There is obviously a moral obligation to provide new and better treatments for patients. But there are also obstacles on the road, regulatory as well as technical. If the problem of standardization, in particular of induced pluripotent stem cell lines, is not addressed, this will create regulatory hurdles as long as the FDA regards every cell line as a new treatment. Moreover, if cell therapies are to be commercially successful and affordable, solutions to the problem of scaling up have to be found.
(Goran Hermeren, Prof. em. Medical ethics, Lund University)
No comments:
Post a Comment